Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
about
Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals
description
scientific article published on 22 August 2019
@en
name
Prospective validation of the ...... natalizumab extended intervals
@en
type
label
Prospective validation of the ...... natalizumab extended intervals
@en
prefLabel
Prospective validation of the ...... natalizumab extended intervals
@en
P2093
P50
P1433
P1476
Prospective validation of the ...... natalizumab extended intervals
@en
P2093
Best-MS Study Group
Béatrice Pignolet
Christine Lebrun-Frenay
Damien Biotti
David Brassat
Florence Bucciarelli
Guillaume Mathey
Heinz Wiendl
Ingrid Meinl
Jean Pelletier
P304
P356
10.1212/WNL.0000000000008135
P577
2019-08-22T00:00:00Z